For the Inventor, By the Inventor

Enter assignee name

Heidelberg, Germany

Ruprecht-Karls-Universitat Heidelberg

USPTO Granted Patents = 63

CIPO Patents = 5

EPO Patents = 88

Forward Citations = 123

Loading Chart...

Loading Chart...

166 inventors (with patents filed for the assignee):

Walter Mier (9 out of 22 patents)

Stephan Urban (8 out of 13 patents)

Hugo Katus (8 out of 15 patents)

4. Jean Rommelaere (7 out of 33 patents)

5. Uwe Haberkorn (7 out of 20 patents)

6. Barbara Leuchs (4 out of 14 patents)

7. Karsten Geletneky (4 out of 12 patents)

8. Michael Dahm (4 out of 9 patents)

9. Matthias Eder (4 out of 13 patents)

10. Klaus Kopka (4 out of 13 patents)

11. Martin Schäfer (4 out of 6 patents)

12. Ulrike Bauder-Wüst (4 out of 6 patents)

13. Michael Eisenhut (4 out of 10 patents)

14. Martina Benesova (4 out of 9 patents)

15. Antonio Marchini (4 out of 9 patents)

Core Competencies:

Lipopeptides

Oncolytic Virus Therapy

Cyclic Peptides

Cancer Biomarkers

Gene Therapy Vectors

Hydrophobic Modified Peptides

MicroRNA Targets

Prostate Cancer Imaging

Cardiovascular Disease Treatments

Malaria Vaccines

Epigenetic Signatures

B-type Plexin Antagonists

63 patents: Sort by Forward Citations

1. 12370237 - Lipopeptides for use in treating liver diseases and cardiovascular diseases (2025-07-29),

2. 11964015 - Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor (2024-04-23),

3. 11401304 - Cyclic NTCP-targeting peptides and their uses as entry inhibitors (2022-08-02),

4. 11369669 - Measles virus encoding a tumor antigen (2022-06-28),

5. 11324788 - Parvovirus formulation for treating tumors (2022-05-10),

6. 11312943 - ABHD5 and partial HDAC4 fragments and variants as a therapeutic approach for the treatment of cardiovascular diseases (2022-04-26),

7. 11274132 - Combined preparations of PKM2 modulators and HMGB1 (2022-03-15),

8. 11202833 - Methylglyoxal-scavenging cyclic peptides and their use for the prevention and treatment of diseases associated with elevated methylglyoxal levels (2021-12-21),

9. 11045564 - Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer (2021-06-29),

10. 11027013 - Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor (2021-06-08),

11. 10988795 - Synthesis of double-stranded nucleic acids (2021-04-27),

12. 10967044 - Lipopeptides for use in treating liver diseases and cardiovascular diseases (2021-04-06),

13. 10941451 - Biomarker panel for the detection of cancer (2021-03-09),

14. 10792329 - S100 based treatment of cardiac power failure (2020-10-06),

15. 10682402 - MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer (2020-06-16),

Ruprecht-Karls-Universität Heidelberg, founded in 1386, is Germany's oldest university and one of the world's top research universities. It offers a wide range of academic programs across various disciplines including humanities, social sciences, natural sciences, and medicine. The university is known for its excellent research facilities, international collaborations, and innovative teaching methods.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

63 Patents

#6 in Heidelberg

#930 in Germany

#11,331 in the World

Heidelberg, Germany

Ruprecht-Karls-Universitat Heidelberg

Forward Citations = 123

166 inventors:

Walter Mier (9 out of 22 patents)

Stephan Urban (8 out of 13 patents)

Hugo Katus (8 out of 15 patents)

4. Jean Rommelaere (7 out of 33 patents)

5. Uwe Haberkorn (7 out of 20 patents)

Please report any incorrect information to support@idiyas.com

Loading…